Dr. Ziba Rahbar is an internationally board-certified dermatologist and an American board-certified dermatopathologist and AP/CP pathologist. She completed a postdoctoral research fellowship in cutaneous lymphoma with Dr. Youn Kim at Stanford University, followed by a clinical and advanced dermatopathology fellowship at MD Anderson Cancer Center, with a focus on cutaneous T-cell lymphoma (CTCL). Most recently, she served as Associate Pathologist and Dermatopathology Faculty at Mass General Brigham, Dana-Farber Cancer Institute, and Harvard Medical School.
🏥 University Affiliation, City, Country: Boston, MA, USA
🧪 Area of Focus in Clinical Practice and Research: Variability of biomarkers in skin specimens in mycosis fungoides and Sézary syndrome (MF/SS); Primary cutaneous lymphomas and lymphoproliferative disorders with T-follicular helper phenotype; and novel diagnostic markers to improve dermatopathological diagnosis
🔎 Looking forward to in the field of cutaneous lymphomas and at the 6th WCCL: Reconnecting with the community of cutaneous lymphoma, learning from recent advances in the field, and acknowledging the contributions and mentorship of those who have shaped our collective progress.
💭 What are you passionate about in medicine or recreationally? Problem-solving and making a meaningful impact on patient outcomes and well-being.
🏆 A short story or academic achievement you are proud of: Key achievements include serving as a clinical liaison in the launch of the PROCLIPI application developed at Stanford University; leading a seminal study on the variability of biomarker expression by IHC in MF/SS that supports expanding the benefit of targeted therapies beyond arbitrary expression thresholds; and co-pioneering the inaugural Multidisciplinary Tumor Board of Cutaneous T-cell Lymphoma at Brigham and Women’s Hospital and Dana-Farber Cancer Institute.
🌟 Secret to career success: Grit